MSRB2

Summary

MSRB2 (methionine sulfoxide reductase B2, HGNC:17061) is a protein-coding gene on chromosome 10p12.2, encoding Methionine-R-sulfoxide reductase B2, mitochondrial (Q9Y3D2). Methionine-sulfoxide reductase that specifically reduces methionine (R)-sulfoxide back to methionine.

Predicted to enable actin binding activity; peptide-methionine (R)-S-oxide reductase activity; and zinc ion binding activity. Predicted to be involved in actin filament polymerization and protein repair. Located in mitochondrion.

Source: NCBI Gene 22921 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 27 total
• Druggable target: yes
• MANE Select transcript: NM_012228

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17061
Approved symbol	MSRB2
Name	methionine sulfoxide reductase B2
Location	10p12.2
Locus type	gene with protein product
Status	Approved
Aliases	PILB, CGI-131, CBS1, CBS-1
Ensembl gene	ENSG00000148450
Ensembl biotype	protein_coding
OMIM	613782
Entrez	22921

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 3 protein_coding, 1 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000376510, ENST00000468633, ENST00000472663, ENST00000900183, ENST00000900184

RefSeq mRNA: 1 — MANE Select: NM_012228 NM_012228

CCDS: CCDS41495

Canonical transcript exons

ENST00000376510 — 5 exons

Exon	Start	End
ENSE00000985342	23104144	23104244
ENSE00000985343	23110242	23110318
ENSE00001470753	23120758	23122013
ENSE00001540262	23095579	23095726
ENSE00003644526	23119304	23119451

Expression profiles

Bgee: expression breadth ubiquitous, 288 present calls, max score 98.62.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 22.2740 / max 197.7805, expressed in 1801 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
104269	21.0878	1797
104270	0.8430	591
104268	0.3432	139

Top tissues by expression

288 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
heart right ventricle	UBERON:0002080	98.62	gold quality
apex of heart	UBERON:0002098	98.55	gold quality
vena cava	UBERON:0004087	97.78	gold quality
cardiac ventricle	UBERON:0002082	97.74	gold quality
heart left ventricle	UBERON:0002084	97.71	gold quality
right atrium auricular region	UBERON:0006631	97.64	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	97.37	gold quality
biceps brachii	UBERON:0001507	97.26	gold quality
triceps brachii	UBERON:0001509	97.21	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	97.04	gold quality
diaphragm	UBERON:0001103	96.93	gold quality
heart	UBERON:0000948	96.70	gold quality
saphenous vein	UBERON:0007318	96.63	gold quality
body of tongue	UBERON:0011876	96.60	gold quality
cardiac atrium	UBERON:0002081	96.41	gold quality
hindlimb stylopod muscle	UBERON:0004252	96.31	gold quality
nucleus accumbens	UBERON:0001882	96.09	gold quality
gluteal muscle	UBERON:0002000	96.07	gold quality
cranial nerve II	UBERON:0000941	96.04	gold quality
substantia nigra pars compacta	UBERON:0001965	96.03	gold quality
amygdala	UBERON:0001876	95.93	gold quality
superior vestibular nucleus	UBERON:0007227	95.93	gold quality
putamen	UBERON:0001874	95.90	gold quality
substantia nigra pars reticulata	UBERON:0001966	95.82	gold quality
lateral globus pallidus	UBERON:0002476	95.82	gold quality
ventral tegmental area	UBERON:0002691	95.74	gold quality
hypothalamus	UBERON:0001898	95.73	gold quality
right lobe of liver	UBERON:0001114	95.68	gold quality
caudate nucleus	UBERON:0001873	95.57	gold quality
lateral nuclear group of thalamus	UBERON:0002736	95.43	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	9.92

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

41 targeting MSRB2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-6759-5P	99.99	66.54	785
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-6768-5P	99.92	67.36	1942
HSA-MIR-1297	99.91	73.41	3162
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-26A-5P	99.78	73.52	2303
HSA-MIR-26B-5P	99.78	73.51	2305
HSA-MIR-4465	99.71	72.56	2096
HSA-MIR-6892-3P	99.68	66.40	1178
HSA-MIR-1251-3P	99.64	67.21	1408
HSA-MIR-12123	99.52	71.79	2990
HSA-MIR-6833-5P	99.50	68.93	1161
HSA-MIR-203A-3P	99.49	70.56	2806
HSA-MIR-4687-3P	99.48	66.41	968
HSA-MIR-6882-5P	99.35	71.13	1206
HSA-MIR-3606-5P	99.31	69.67	1168
HSA-MIR-3064-5P	99.26	66.13	1497
HSA-MIR-3085-3P	99.26	66.16	1490
HSA-MIR-6504-5P	99.26	65.95	1487
HSA-MIR-4727-5P	99.23	67.55	1154
HSA-MIR-8065	99.19	70.38	1289
HSA-MIR-4520-2-3P	99.14	69.28	1009
HSA-MIR-877-3P	99.09	68.10	1637
HSA-MIR-6804-5P	98.39	65.77	1084
HSA-MIR-654-3P	98.38	67.61	905
HSA-MIR-1262	98.17	66.52	757
HSA-MIR-4701-3P	98.17	66.25	788
HSA-MIR-6736-5P	98.17	66.43	760
HSA-MIR-7850-5P	98.12	67.28	1111

Literature-anchored findings (GeneRIF, showing 15)

• CBS1, a methionine sulfoxide reductase of type B, is most abundant in muscle tissues, especially in the heart and thereby shows an expression pattern different to the human methionine sulfoxide reductase A (PMID:12220640)
• MSRB is down-regulated during cell aging. (PMID:14759519)
• hMSRB2 expression was weak in brain, but strong in heart, skeletal muscle, and smooth muscle-containing organs (digestive system, bladder), lung and aorta, while hMSRB1 displayed a higher expression in liver and kidney (PMID:14980072)
• showed the expression and function of both sulfoxide reductases together with thioredoxin reductase in the cytosol as well as in the nucleus of epidermal melanocytes which are especially sensitive to reactive oxygen (PMID:16480945)
• Methionine sulfoxide reductases A and B are seriously affected by hydrogen peroxide accumulation in acute vitiligo. (PMID:17943184)
• upon oxidative stress, the overexpression of methionine sulfoxide reductase B2 leads to the preservation of mitochondrial integrity by decreasing the intracellular reactive oxygen species build-up through its scavenging role (PMID:18424444)
• almost absent catalase and methionine sulfoxide reductase A and B protein expression in human gray/white scalp hair shafts in association with a functional loss of methionine sulfoxide repair in the entire gray hair follicle (PMID:19237503)
• MSR enzymes are differentially expressed in human skin. (PMID:19542914)
• Data show that glutaredoxin acts as a reductant for methionine sulfoxide reductases A and B (MsrA and MsrB) with or without resolving cysteine. (PMID:22634633)
• Silencing the expression of the main Msr elements-MsrA, MsrB1, or MsrB2 exacerbates sensitivity toward oxidative stress. (PMID:23988788)
• the mitochondrial methionine-R-sulfoxide reductase B2 (MSRB2) is a specific interaction partner of LG72. (PMID:25078755)
• this study we have identified, for the first time, compounds structurally related to the natural products fusaricidins that markedly activate recombinant bovine and human MsrA and human MsrB. (PMID:26718410)
• the role for mitochondrial MSRB2 in Alzheimer’s disease pathology is indispensible. (PMID:31078523)
• Release of the enzyme MsrB2 from damaged mitochondria, initiating autophagosome formation, represents a novel regulatory mechanism for oxidative stress-induced mitophagy. (PMID:31282614)
• MSRB2 Ameliorates H2O2-induced Chondrocyte Oxidative Stress and Suppresses Apoptosis in Osteoarthritis. (PMID:38638027)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
mus_musculus	Msrb2	ENSMUSG00000023094
rattus_norvegicus	Msrb2	ENSRNOG00000016873
drosophila_melanogaster	MsrA	FBGN0000565
caenorhabditis_elegans		WBGENE00018393

Paralogs (3): MSRB3 (ENSG00000174099), MSRA (ENSG00000175806), MSRB1 (ENSG00000198736)

Protein

Protein identifiers

Methionine-R-sulfoxide reductase B2, mitochondrial — Q9Y3D2 (reviewed: Q9Y3D2)

All UniProt accessions (2): Q9Y3D2, H0YE51

UniProt curated annotations — full annotation on UniProt →

Function. Methionine-sulfoxide reductase that specifically reduces methionine (R)-sulfoxide back to methionine. While in many cases, methionine oxidation is the result of random oxidation following oxidative stress, methionine oxidation is also a post-translational modification that takes place on specific residue. Upon oxidative stress, may play a role in the preservation of mitochondrial integrity by decreasing the intracellular reactive oxygen species build-up through its scavenging role, hence contributing to cell survival and protein maintenance.

Subunit / interactions. Interacts with DAOA; the interaction is direct.

Subcellular location. Mitochondrion.

Tissue specificity. Ubiquitous. Detected in retina, ocular ciliary body, skeletal muscle, heart, colon, bone marrow, cerebellum, small intestine, fetal brain, fetal liver, kidney, spinal cord, lung, placenta and prostate.

Cofactor. Binds 1 zinc ion per subunit.

Similarity. Belongs to the MsrB Met sulfoxide reductase family.

RefSeq proteins (1): NP_036360* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002579	Met_Sox_Rdtase_MsrB_dom	Domain
IPR011057	Mss4-like_sf	Homologous_superfamily
IPR028427	Met_Sox_Rdtase_MsrB	Family

Pfam: PF01641

Enzyme classification (BRENDA):

• EC 1.8.4.12 — peptide-methionine (R)-S-oxide reductase (BRENDA: 101 organisms, 214 substrates, 7 inhibitors, 64 Km, 65 kcat entries)
• EC 1.8.4.B3 — (BRENDA: organisms, substrates, inhibitors, Km, kcat entries)

Substrate kinetics (BRENDA)

19 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
THIOREDOXIN	0.004–7	9
L-METHIONINE-(R)-S-OXIDE	0.054–1.3	8
DABSYL-L-METHIONINE (R)-S-OXIDE	0.03–0.085	7
DABSYL-L-METHIONINE (R)-SULFOXIDE	0.02–0.06	6
N-ACETYL-L-METHIONINE-(R)-S-OXIDE	0.043–0.429	6
DITHIOTHREITOL	0.0091–2	4
L-METHIONINE (R)-SULFOXIDE	1.451–67	3
TRYPAREDOXIN I	0.0016–0.0021	3
ACETYL-L-METHIONINE (R)-SULFOXIDE N-METHYL ESTER	0.14–2.2	2
N-ACETYL-L-METHIONINE (R)-SULFOXIDE	0.049	2
(S)-1-NONEN-4-OL	1.2	1
CDSP32	0.0002	1
GLUTAREDOXIN	0.0028	1
GLUTAREDOXIN C4	0.0068	1
GLUTAREDOXIN S12	0.0005	1

Catalyzed reactions (Rhea), 2 shown:

• [thioredoxin]-disulfide + L-methionine + H2O = L-methionine (R)-S-oxide + [thioredoxin]-dithiol (RHEA:21260)
• L-methionyl-[protein] + [thioredoxin]-disulfide + H2O = L-methionyl-(R)-S-oxide-[protein] + [thioredoxin]-dithiol (RHEA:24164)

UniProt features (10 total): binding site 4, transit peptide 1, chain 1, domain 1, active site 1, sequence variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9Y3D2-F1	82.25	0.65

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 169 (nucleophile)

Ligand- & substrate-binding residues (4): 90; 93; 146; 149

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-5676934	Protein repair
R-HSA-392499	Metabolism of proteins

MSigDB gene sets: 184 (showing top): BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_1, GOBP_ACTIN_FILAMENT_ORGANIZATION, KINSEY_TARGETS_OF_EWSR1_FLII_FUSION_DN, SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_DN, GOMF_ACTIN_BINDING, GRYDER_PAX3FOXO1_ENHANCERS_IN_TADS, chr10p12, PARENT_MTOR_SIGNALING_UP, CHANDRAN_METASTASIS_TOP50_DN, KRIGE_RESPONSE_TO_TOSEDOSTAT_24HR_UP, GOMF_OXIDOREDUCTASE_ACTIVITY_ACTING_ON_A_SULFUR_GROUP_OF_DONORS_DISULFIDE_AS_ACCEPTOR, GOMF_CYTOSKELETAL_PROTEIN_BINDING, RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_DN

GO Biological Process (3): response to oxidative stress (GO:0006979), actin filament polymerization (GO:0030041), protein repair (GO:0030091)

GO Molecular Function (8): actin binding (GO:0003779), zinc ion binding (GO:0008270), peptide-methionine (R)-S-oxide reductase activity (GO:0033743), L-methionine (R)-S-oxide reductase activity (GO:0033745), protein binding (GO:0005515), oxidoreductase activity (GO:0016491), oxidoreductase activity, acting on a sulfur group of donors, disulfide as acceptor (GO:0016671), metal ion binding (GO:0046872)

GO Cellular Component (3): cytoplasm (GO:0005737), mitochondrion (GO:0005739), cytosol (GO:0005829)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Metabolism of proteins	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
oxidoreductase activity, acting on a sulfur group of donors, disulfide as acceptor	2
cellular anatomical structure	2
cytoplasm	2
response to stress	1
actin polymerization or depolymerization	1
protein polymerization	1
protein metabolic process	1
cytoskeletal protein binding	1
transition metal ion binding	1
catalytic activity, acting on a protein	1
binding	1
catalytic activity	1
oxidoreductase activity, acting on a sulfur group of donors	1
cation binding	1
intracellular anatomical structure	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

1480 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MSRB2	MSRA	Q9UJ68	916
MSRB2	TXN	P10599	741
MSRB2	H7C2H4	H7C2H4	719
MSRB2	P0DN79	P0DN79	715
MSRB2	TJAP1	Q5JTD0	621
MSRB2	CNNM2	Q9H8M5	557
MSRB2	SELENOT	P62341	541
MSRB2	GLRX	P35754	519
MSRB2	SELENOF	O60613	518
MSRB2	CAMP	P49913	514
MSRB2	CLCN1	P35523	512
MSRB2	SELENOO	Q9BVL4	496
MSRB2	MTRR	Q9UBK8	477
MSRB2	DAOA	P59103	470
MSRB2	SELENOM	Q8WWX9	447
MSRB2	SEPHS2	Q99611	447

IntAct

61 interactions, top by confidence:

A	B	Type	Score
TRAF2	MSRB2	psi-mi:“MI:0915”(physical association)	0.560
MSRB2	APBB2	psi-mi:“MI:0915”(physical association)	0.560
MSRB2	APOE	psi-mi:“MI:0915”(physical association)	0.560
MSRB2		psi-mi:“MI:0915”(physical association)	0.560
ELAVL4	MSRB2	psi-mi:“MI:0915”(physical association)	0.560
MSRB2	GFAP	psi-mi:“MI:0915”(physical association)	0.560
MSRB2	NDUFV2	psi-mi:“MI:0915”(physical association)	0.560
MSRB2	PMP22	psi-mi:“MI:0915”(physical association)	0.560
MSRB2	NDRG1	psi-mi:“MI:0915”(physical association)	0.560
PEX26	MSRB2	psi-mi:“MI:0915”(physical association)	0.560
MSRB2	JPH3	psi-mi:“MI:0915”(physical association)	0.560
SNCA	MSRB2	psi-mi:“MI:0915”(physical association)	0.560
HTT	MSRB2	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (65): MSRB2 (Two-hybrid), MSRB2 (Affinity Capture-MS), MSRB2 (Affinity Capture-MS), MSRB2 (Two-hybrid), MSRB2 (Co-fractionation), MSRB2 (Co-fractionation), MSRB2 (Co-fractionation), MSRB2 (Co-fractionation), MSRB2 (Co-fractionation), MSRB2 (Co-fractionation), MSRB2 (Co-fractionation), MSRB2 (Co-fractionation), MSRB2 (Co-fractionation), MSRB2 (Co-fractionation), MSRB2 (Co-fractionation)

ESM2 similar proteins: B4GUZ2, O49707, O64903, O76454, O81263, P00257, P10109, P10606, P24483, P25566, P46656, P54150, P54151, Q01H90, Q05B87, Q08C57, Q0DC89, Q16595, Q1JPN0, Q2GNZ6, Q2HVD6, Q4FZX5, Q4P4Y2, Q5BFH3, Q5NTH3, Q5R930, Q5REG2, Q69SV0, Q6AUK5, Q6EU10, Q6NW52, Q6Z690, Q6ZQ88, Q78J03, Q7XUR2, Q84JT6, Q8BU85, Q8GWF4, Q8INK9, Q8IXL7

Diamond homologs: A0K833, A1JQG8, A1V4U8, A1VNB7, A2SBI6, A2SGN7, A3M4Q3, A4G5V5, A4JEZ1, A4XVB1, A5F6R2, A5GQT3, A5W756, A6T7R0, A6V3R3, A7Z5S1, A8A0X0, A9AJS6, B0BYW4, B0KUQ0, B0VC45, B0VR86, B1IPF3, B1J4W5, B1JTT6, B1YRN6, B2HYT2, B2I8Y4, B3PK10, B4EBK9, B5XS71, B7H3X2, B7I415, B7LQ21, B7M1J2, B7UUZ9, B8GMG5, B8GY23, C1DRM1, C3K735

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

27 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	19
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

922 predictions. Top by Δscore:

Variant	Effect	Δscore
10:23104250:C:G	donor_gain	1.0000
10:23102641:TTA:T	donor_gain	0.9900
10:23104140:ACAG:A	acceptor_gain	0.9900
10:23104142:AG:A	acceptor_gain	0.9900
10:23104143:GG:G	acceptor_gain	0.9900
10:23104242:CCGG:C	donor_loss	0.9900
10:23104243:CGG:C	donor_loss	0.9900
10:23104245:G:GG	donor_gain	0.9900
10:23104245:G:GT	donor_loss	0.9900
10:23104246:T:TT	donor_loss	0.9900
10:23110240:A:AG	acceptor_gain	0.9900
10:23110241:G:GA	acceptor_gain	0.9900
10:23110315:TCAG:T	donor_loss	0.9900
10:23110316:CAG:C	donor_loss	0.9900
10:23110316:CAGGT:C	donor_gain	0.9900
10:23110317:AGGTA:A	donor_gain	0.9900
10:23110318:GG:G	donor_loss	0.9900
10:23110318:GGT:G	donor_gain	0.9900
10:23110319:G:GC	donor_loss	0.9900
10:23110320:T:G	donor_loss	0.9900
10:23113728:A:G	acceptor_gain	0.9900
10:23119302:A:AG	acceptor_gain	0.9900
10:23119303:G:GG	acceptor_gain	0.9900
10:23104137:A:AG	acceptor_gain	0.9800
10:23104139:TACA:T	acceptor_loss	0.9800
10:23104141:CA:C	acceptor_loss	0.9800
10:23104142:A:AT	acceptor_loss	0.9800
10:23110237:TTCA:T	acceptor_loss	0.9800
10:23110238:TCAG:T	acceptor_loss	0.9800
10:23110240:A:C	acceptor_loss	0.9800

AlphaMissense

1163 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:23119344:T:C	F113L	0.998
10:23119346:T:A	F113L	0.998
10:23119346:T:G	F113L	0.998
10:23110314:T:C	F98L	0.997
10:23110316:C:A	F98L	0.997
10:23110316:C:G	F98L	0.997
10:23120815:T:C	F168L	0.996
10:23120817:T:A	F168L	0.996
10:23120817:T:G	F168L	0.996
10:23110315:T:C	F98S	0.995
10:23120782:T:C	F157L	0.995
10:23120784:T:A	F157L	0.995
10:23120784:T:G	F157L	0.995
10:23104219:T:A	V65D	0.993
10:23119335:T:A	W110R	0.993
10:23119335:T:C	W110R	0.993
10:23119337:G:C	W110C	0.993
10:23119337:G:T	W110C	0.993
10:23119345:T:C	F113S	0.993
10:23120826:C:A	N171K	0.993
10:23120826:C:G	N171K	0.993
10:23120827:A:C	S172R	0.993
10:23120829:T:A	S172R	0.993
10:23120829:T:G	S172R	0.993
10:23110315:T:G	F98C	0.992
10:23119345:T:G	F113C	0.992
10:23120813:G:T	R167M	0.992
10:23120769:T:A	H152Q	0.991
10:23120769:T:G	H152Q	0.991
10:23120816:T:C	F168S	0.991

dbSNP variants (sampled 300 via entrez): RS1000286192 (10:23113507 G>A), RS1000391740 (10:23122378 C>A,T), RS1000538041 (10:23093738 A>G), RS1000592923 (10:23117858 T>C), RS1000661711 (10:23110811 A>C), RS1000851281 (10:23095117 A>T), RS1000953926 (10:23098591 G>A,T), RS1000956281 (10:23116326 A>G), RS1001165 (10:23099982 G>A,C,T), RS1001232413 (10:23101881 A>C), RS1001346642 (10:23102147 GAC>G), RS1001476599 (10:23107375 C>A), RS1001776344 (10:23107557 T>C), RS1001778990 (10:23113359 C>A), RS1001833977 (10:23118346 T>TG,TGG)

Disease associations

OMIM: gene MIM:613782 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST001762_687	Obesity-related traits	3.000000e-06
GCST002875_43	Diisocyanate-induced asthma	2.000000e-06

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004810	interleukin-6 measurement
EFO:0006995	response to diisocyanate

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3509603 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

49 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, affects expression	4
bisphenol A	decreases expression, decreases methylation, affects cotreatment, increases expression	3
Benzo(a)pyrene	decreases methylation, increases expression	2
tert-Butylhydroperoxide	decreases expression, decreases reaction, decreases response to substance	2
GSK-J4	decreases expression	1
bisphenol F	affects cotreatment, increases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
butyraldehyde	decreases expression	1
salvianolic acid B	decreases reaction, decreases expression	1
perfluorooctane sulfonic acid	increases expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
ICG 001	increases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
bisphenol S	affects cotreatment, increases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Arsenic Trioxide	decreases expression	1
Acetaminophen	decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Azacitidine	increases expression	1
Cadmium	increases abundance, increases expression	1
Curcumin	decreases expression, decreases reaction	1
Dexamethasone	affects cotreatment, increases expression	1
Diethylstilbestrol	decreases expression	1
Dithiothreitol	increases reduction	1
Doxorubicin	decreases expression	1
Estradiol	affects expression	1
Ethyl Methanesulfonate	increases expression	1
Indomethacin	affects cotreatment, increases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 admet

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL3528407	ADMET	Drug metabolism assessed as human MSRB2-mediated reduced product formation	Studies on the metabolism and biological activity of the epimers of sulindac. — Drug Metab Dispos

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.